Treat cancer and reverse fibrosis

We are a clinical-stage biotech company with a mission to treat cancer and reverse fibrosis. To this end, we are rapidly advancing our pipeline of anti-Claudin-1 antibody-drug conjugates (ADCs) and monoclonal antibodies.

Our team is committed to unlocking the broad potential of our therapeutic target Claudin-1 and bringing new treatments to those in need.

Transformative Claudin-1 antibodies

We are the world leader in developing anti-Claudin-1 treatment. Our first-in-class antibodies specifically target exposed Claudin-1 to open the stiff extracellular matrix, block disease signaling, and in cancer, selectively kill tumor cells.

R&D pipeline

We have developed a promising pipeline of anti-Claudin-1 antibody-drug conjugates (ADCs) and antibodies. Our clinical candidates include ADC ALE.P02 for squamous cancers and monoclonal antibody lixudebart for organ fibrosis. Beyond the clinical assets, our preclinical programs feature other anti-Claudin-1 modalities including other ADCs.

Inspired leadership

Our carefully chosen team values collaboration, hard work and shares the belief that anti-Claudin-1 therapies will make a difference for patients. Our highly experienced leadership team is supported by a Board of Directors and a Scientific Advisory Board made up of industry veterans, entrepreneurs and esteemed scientists.

Alentis news

October 15, 2025

ALENTIS APPOINTS MARK PRUZANSKI AS CEO

January 9, 2054

POSITIVE TOPLINE RESULTS FOR TWO FIBROSIS STUDIES OF LIXUDEBART (ALE.F02)

November 18, 2024

ALENTIS RECEIVES FDA FAST TRACK DESIGNATION FOR ALE.P02